New Therapeutic Drug Monitoring Test for Interleukin‐23 Inhibitor SAN DIEGO, CA / ACCESS Newswire / April 1, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision-guided medicine, ...
Psoriasis results in long-term inflammation in the body. This inflammation stiffens and narrows the arteries, raising the risk of high blood pressure, heart attack, and stroke. Read on. , Health News ...
PRNewswire/ -- ixlayer, a leading cloud-based healthtech platform, with Ipsos, a global leader in market research, have released findings from the inaugural research report, " ixlayer ixInsights 2025: ...
Struggling with dark spots? Learn what causes hyperpigmentation, how to prevent it, and the best treatments—from skincare ...
Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices ...
A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing ...
The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
The researchers found that several types of blood pressure medications—especially ACE inhibitors, beta-blockers, ...
“ Psoriasis is an inflammatory skin disorder, due to an overactive immune system,” said Dr. Omar Noor. “That over active immune system produces inflammation in the skin that causes the skin to develop ...
Spots can also look very different depending on your skin tone. Some pink, red, or brown spots are more obvious on fair to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback